Relapse After Venetoclax-Based Therapy: Early vs Late Management

EP: 1.Recent Guideline Updates in the Frontline Management of CLL

EP: 2.Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

EP: 3.Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

EP: 4.Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

EP: 5.Clinical Insights and Real-World Evidence

EP: 6.Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

EP: 7.Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

EP: 8.Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

EP: 9.Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

Now Viewing

EP: 10.Relapse After Venetoclax-Based Therapy: Early vs Late Management

EP: 11.Progression on BTK Inhibitors: Treatment Options and Considerations

EP: 12.Emerging Agents and Future Strategies in Relapsed/Refractory CLL

EP: 13.Reflections and Future Directions in CLL Management

Video content above is prompted by the following:

• Briefly review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy. (ESMO CLL Guideline Update 2024)
• Briefly comment on the underlying rationale and supporting data (high level) for continuous BTKi therapy in this setting.
  • ALPINE – Brown, et al. ASH 2023. Abstract 202
  • ELEVATE-RR– Seymour, et al. Blood. 2023
  • How do you incorporate these data and recommendations into your treatment approach?

Late Relapse After 1L Venetoclax

• Briefly review recent ESMO guideline updates for managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy.
  • How do you define early versus late relapse, and how does your treatment approach differ for each following venetoclax-based time-limited therapy?
  • At what point do you consider retreatment with venetoclax?